Department of Anesthesia and Intensive Care, Post Graduate Institute of Medical Education & Research, Chandigarh-160012, India.
J Clin Anesth. 2010 Mar;22(2):88-92. doi: 10.1016/j.jclinane.2009.03.011.
To investigate the effect of parecoxib pretreatment with venous occlusion on propofol injection pain.
Prospective, randomized, double-blinded, placebo-controlled study.
Operating room of a tertiary-care medical center.
150 ASA physical status I patients scheduled for elective surgery.
Patients were randomized to three groups of 50 patients each to receive pretreatment with normal saline (Group NS), parecoxib 20 mg (Group P20), or parecoxib 40 mg (Group P40). All groups underwent venous occlusion for two minutes before propofol was injected. All pretreatment drugs were prepared in 5 mL doses.
Pain scores were obtained by a study-blinded observer during propofol injection following the different pretreatment solutions.
Pain scores among the three groups were significantly different (P < or = 0.001). In Group NS, 29 (58%) patients had pain during propofol injection compared with 22 (40%) Group P20 and 13 (26%) Group P40 patients (P < or = 0.005). Pain was significantly reduced in Group P40 (P < or = 0.001) compared with the control group. Moderate to severe pain was experienced by 18 (36%) Group NS and 4 (8%) Group P20 patients, whereas no Group P40 patient experienced moderate or severe pain (P < 0.001). Reduction in pain severity was statistically significant after pretreatment with either parecoxib 20 mg (P = 0.002) or parecoxib 40 mg (P < 0.001).
Parecoxib 40 mg with venous occlusion is effective in reducing the frequency and severity of pain with propofol injection. Pretreatment with 20 mg of parecoxib reduces the severity of propofol injection pain significantly but does not reduce frequency compared with the control group.
研究帕瑞昔布预处理联合静脉闭塞对丙泊酚注射痛的影响。
前瞻性、随机、双盲、安慰剂对照研究。
三级医疗中心手术室。
150 例 ASA Ⅰ级择期手术患者。
患者随机分为三组，每组 50 例，分别接受生理盐水（NS 组）、帕瑞昔布 20 mg（P20 组）或帕瑞昔布 40 mg（P40 组）预处理。所有组患者在注射丙泊酚前均行静脉闭塞 2 分钟。所有预处理药物均以 5 mL 剂量配制。
不同预处理溶液后，由研究盲法观察者在丙泊酚注射时获取疼痛评分。
三组患者的疼痛评分差异有统计学意义（P≤0.001）。在 NS 组中，29 例（58%）患者在丙泊酚注射时出现疼痛，而 P20 组和 P40 组分别有 22 例（40%）和 13 例（26%）患者出现疼痛（P≤0.005）。与对照组相比，P40 组的疼痛明显减轻（P≤0.001）。NS 组有 18 例（36%）患者出现中度至重度疼痛，P20 组有 4 例（8%）患者出现中度至重度疼痛，而 P40 组无患者出现中度或重度疼痛（P＜0.001）。帕瑞昔布 20 mg（P=0.002）或帕瑞昔布 40 mg（P＜0.001）预处理后疼痛严重程度均有统计学意义的降低。
帕瑞昔布 40 mg 联合静脉闭塞可有效减少丙泊酚注射时疼痛的发生频率和严重程度。帕瑞昔布 20 mg 预处理可显著减轻丙泊酚注射痛的严重程度，但与对照组相比，其疼痛发生率无降低。
